Teriflunomide: A novel oral treatment for relapsing multiple sclerosis

Expert Opinion on Pharmacotherapy

Volumn 15, Issue 7, 2014, Pages 1019-1027

  Sartori, Arianna ^a   Carle, Dawn ^b   Freedman, Mark S ^b  

^a UNIVERSITY OF TRIESTE   (Italy)

^b UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Disease modifying therapy; Oral agent; Relapsing multiple sclerosis; Teriflunomide

Indexed keywords

BETA1A INTERFERON; TERIFLUNOMIDE;

BREAST CANCER; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG HALF LIFE; DRUG INTERMITTENT THERAPY; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; FOOD AND DRUG ADMINISTRATION; HAIR LOSS; HEADACHE; HUMAN; MULTIPLE SCLEROSIS; NAUSEA; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; RECURRENT DISEASE; REVIEW;

ADMINISTRATION, ORAL; CLINICAL TRIALS AS TOPIC; CROTONATES; DRUG EVALUATION; HUMANS; INTERFERON-BETA; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; TOLUIDINES;

EID: 84899437209     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2014.902936     Document Type: Review

References (54)

1. Compston A, Coles A. Multiple sclerosis. Lancet 2008;372:1502-17
2. Pelletier D, Hafler DA. Fingolimod for multiple sclerosis. N Engl J Med 2012;366:339-47
3. Selmaj K, Li DK, Hartung HP, et al. Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study. Lancet Neurol 2013;12:756-67
4. Freedman MS, Boster A, Fernandez O, et al. Long-term efficacy, safety and tolerability of ponesimod in patients with relapsing-remitting multiple sclerosis. Neurology 2013;80:P01.156
5. Vollmer T, Selmaj K, Bar-Or A, et al. A double-blind, placebo-controlled, Phase 2, 26-week DreaMS trial of a selective S1P receptor agonist ONO-4641 in patients with relapsing-remitting multiple sclerosis. Neurology 2012;78(Suppl 1):013
6. Gold R, Kappos L, Arnold DL, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012;367:1098-107
7. Ermis U, Weis J, Schulz JB. PML in a patient treated with fumaric acid. N Engl J Med 2013;368:1657-8
8. Van Oosten BW, Killestein J, Barkhof F, et al. PML in a patient treated with dimethyl fumarate from a compounding pharmacy. N Engl J Med 2013;368:1658-9
9. Erratum, N Engl J Med 2013;368:1950
10. Comi G, Jeffery D, Kappos L, et al. Placebo-controlled trial of oral laquinimod for multiple sclerosis. N Engl J Med 2012;366:1000-9
11. Warnke C, Meyer zuHörste G, Hartung H, et al. Review of teriflunomide and its potential in the treatment of multiple sclerosis. Neuropsychiatr Dis Treat 2009;5:333-40
12. Li L, Liu J, Delohery T, et al. The effects of teriflunomide on lymphocyte subpopulations in human peripheral blood mononuclear cells in vitro. J Neuroimmunol 2013;265:82-90
13. Leist T, Freedman MS, Kappos L, et al. Pooled safety data from three placebo-controlled teriflunomide studies. Mult Scler 2013;19:74 P633
14. Bar-Or A, Freedman MS, Kremenchutzky M, et al. Teriflunomide effect on immune response to influenza vaccine in patients with multiple sclerosis. Neurology 2013;81:552-8
15. Bar-Or A, Larouche R, Legrand B, et al. Immune response to neoantigen and recall antigens in healthy subjects receiving teriflunomide. Mult Scler 2013;19:74 P622
16. Posevitz V, Chudyka D, Kurth F, et al. The anti-proliferative effect of teriflunomide correlates with antigen affinity. Mult Scler 2013;19:74 P974
17. Claussen MC, Korn T. Immune mechanisms of new therapeutic strategies in MS: teriflunomide. Clin Immunol 2012;142:49-56
18. Merrill JE, Hanak S, Pu SF, et al. Teriflunomide reduces behavioural, electrophysiological, and histopathological deficits in the Dark Agouti rat model of experimental autoimmune encephalomyelitis. J Neurol 2009;256:89-103
19. Iglesias-Bregna D, Hanak S, Ji Z, et al. Effects of prophylactic and therapeutic teriflunomide in transcranial magnetic stimulation-induced motor-evoked potentials in the dark agouti rat model of experimental autoimmune encephalomyelitis. J Pharmacol Exp Ther 2013;347:203-11
20. Ringheim GE, Lee L, Laws-Ricker L, et al. Teriflunomide attenuates immunopathological changes in the dark agouti rat model of experimental autoimmune encephalomyelitis. Front Neurol 2013;30(4):169
21. Pachner A, Keyes L, Gilli F. Teriflunomide treatment decreases chemokine expression in the CNS in the Theiler's virus-induced demyelinating disease model of multiple sclerosis. Mult Scler 2013;19:74 P369
22. Limsakun T, Menguy-Vacheron F. Pharmacokinetics of oral teriflunomide, a novel oral disease-modifying agent under investigation for the treatment of multiple sclerosis. Neurology 2010;74:P05.032
23. Limsakun T, Menguy-Vacheron F. Effects of cholestyramine on the elimination of teriflunomide in healthy male volunteers. Mult Scler 2011;16:P11
24. Miller A, Turpault S, Menguy-Vacheron F. Rapid elimination procedure of teriflunomide with cholestyramine or activated charcoal. In Fourth Cooperative Meeting of CMSC and ACTRIMS; 30 May-2 June 2012; San Diego, CA, USA. P10
25. O'Connor PW, Li D, Freedman MS, et al. A phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology 2006;66:894-900
26. O'Connor P, Wolinsky JS, Confavreux C, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med 2011;365:1293-303
27. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50:121-7
28. Wolinsky JS, Narayana PA, Nelson F, et al. Magnetic resonance imaging outcomes from a phase III trial of teriflunomide. Mult Scler 2013;19:1310-19
29. Miller AE, O'Connor P, Wolinsky JS, et al. Pre-specified subgroup analyses of a placebo-controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis. Mult Scler 2012;18:1625-32
30. Freedman MS, O'Connor P, Wolinsky JS, et al. Teriflunomide increases the proportion of patients free from disease activity in the TEMSO phase III study. Neurology 2012;78:PD5.00
31. O'Connor P, Lublin FD, Wolinsky JS, et al. Teriflunomide reduces relapse-related neurological sequelae, hospitalizations and steroid use. J Neurol 2013;260:2472-80
32. Freedman MS, Wolinsky J, Comi G, et al. Long-term safety and efficacy of teriflunomide in patients with relapsing forms of multiple sclerosis in the TEMSO extension trial. Mult Scler 2013;19:74 P544
33. Confavreux C, O'Connor P, Comi G, et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol 2014;13(3):247-56
34. O'Connor P, Lublin F, Wolinsky J, et al. Teriflunomide reduces relapse-related sequelae, hospitalizations and corticosteroid use: a post-hoc analysis of the phase 3 TOWER study. Neurology 2013;80:P07.109
35. Kappos L, Comi G, Freedman MS, et al. Pooled efficacy data from two phase 3 placebo-controlled trials of oral, oncedaily teriflunomide. Mult Scler 2013;19:74 P618
36. Macdonell R, Lublin F, Comi G, et al. Teriflunomide reduces relapse-related sequelae, severe relapses, hospitalizations and corticosteroid use: pooled data from the phase 3 TEMSO and TOWER studies. Mult Scler 2013;19:74 P1095
37. Panitch H, Goodin DS, Francis G, et al. Randomized, comparative study of interferon beta-1a treatment regimens in MS: the EVIDENCE Trial. Neurology 2002;59:1496-506
38. Vermersch P, Czlonkowska A, Grimaldi LM, et al. Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomized, controlled phase 3 trial. Mult Scler 2013. [Epub ahead of print], doi:10.1177/1352458513507821
39. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011;69:292-302
40. Miller A, Wolinsky J, Kappos L, et al. TOPIC main outcomes: efficacy and safety of once-daily oral teriflunomide in patients with clinically isolated syndrome. Mult Scler 2013;19:18 99
41. Freedman MS, Wolinsky JS, Wamil B, et al. Oral teriflunomide plus glatiramer acetate in relapsing multiple sclerosis. Int J MS Care 2011;13:17
42. Freedman MS, Wolinsky JS, Wamil B, et al. Teriflunomide added to interferon-beta in relapsing multiple sclerosis. A randomized phase II trial. Neurology 2012;78:1877-85
43. Freedman MS, Cheng S, Truffinet P, et al. TERACLES study design: teriflunomide as adjunctive therapy with interferon-beta in patients with relapsing multiple sclerosis. Poster presentation at the Fourth Cooperative Meeting of CMSC and ACTRIMS; 30 May-2 June 2012; San Diego, CA, USA. P9
44. Confavreux C, Li DK, Freedman MS, et al. Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years. Mult Scler 2012;18:1278-89
45. Freedman MS, Delhay J-L, Benamor M. Gastrointestinal symptoms infrequently led to discontinuation of teriflunomide therapy. Poster presentation at the Fourth Cooperative Meeting of CMSC and ACTRIMS; 30 May-2 June 2012; San Diego, CA, USA. P8
46. Freedman MS, Confavreux C, Comi G, et al. Hair thinning associated with teriflunomide therapy is manageable. Poster presentation at the Fourth Cooperative Meeting of CMSC and ACTRIMS; 30 May-2 June 2012; San Diego, CA, USA. P7
47. Kieseier B, Stüve O, Benamor M, et al. Updated pregnancy outcomes from the teriflunomide clinical development programme: retrospective analysis of the teriflunomide clinical trial database. Mult Scler 2013;19:74 P541
48. Davenport L, Czich A, Turpault S. Teriflunomide: no effects on sperm DNA. Mult Scler 2013;19:559 P1187
49. Chambers CD, Johnson DL, Robinson LK, et al. Birth outcomes in women who have taken leflunomide during pregnancy. Arthritis Rheum 2010;62:1494-503
50. Cassina M, Johnson DL, Robinson LK, et al. Pregnancy outcome in women exposed to leflunomide before or during pregnancy. Arthritis Rheum 2012;64:2085-94
51. Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 2012;367:1087-97
52. Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010;362:402-15
53. Durelli L, Verdun E, Barbero P, et al. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 2002;359:1453-60
54. CDEC Final recommendation-Dimethyl Fumarate. 2013. Available from: http://www.cadth. ca/media/cdr/complete/cdr-complete-Tecfidera-September-30-13. pdf [Last accessed 23 January 2014]